Tesamorelin 10MG 

1. Synthetic GHRH Analogue 

Category: Growth Hormone-Releasing Peptides (GHRH Analogues)

TESAMORELIN-10MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

For Research Use Only – Not for Human Consumption

Product Overview

Tesamorelin is a synthetic peptide analogue of human Growth Hormone-Releasing Hormone (GHRH), engineered to stimulate endogenous growth hormone (GH) secretion from the anterior pituitary gland. This research peptide enables the study of GH/IGF-1 axis regulation, body composition modulation, and metabolic disorders. Tesamorelin’s chemical stability and extended half-life make it a preferred model compound for investigating lipid metabolism, visceral adiposity, and muscle tissue growth in laboratory settings.

Tesamorelin Research Summary

Tesamorelin has been extensively studied in metabolic and endocrinological research. It acts as a potent and selective stimulator of the pituitary GHRH receptor, inducing GH release and subsequently elevating circulating insulin-like growth factor-1 (IGF-1). Clinical and preclinical data suggest that Tesamorelin significantly reduces visceral adipose tissue (VAT), improves lipid metabolism, and enhances anabolic processes related to muscle tissue and glucose utilization.

Key research findings include:

• Significant reduction of visceral fat in HIV-associated lipodystrophy studies (NEJM, 2010).
• Improved liver fat and insulin sensitivity in metabolic syndrome models (JAMA, 2014).
• Elevated GH and IGF-1 secretion with minimal adverse metabolic outcomes (PubMed, 2015).
• Potential neuroprotective effects linked to GH-IGF-1 signaling pathways (Neuroendocrinology, 2021).

Applications in Research

• Growth hormone axis and pituitary receptor pathway analysis
• Visceral fat reduction and body composition studies
• Endocrine and metabolic dysfunction models
• Aging and regenerative physiology investigations
• Comparative studies with GHRPs and GH secretagogues

For Research Use Only

This compound is provided exclusively for laboratory and scientific research purposes. It is not approved for human or veterinary use, medical diagnostics, or therapeutic applications. All personnel handling this peptide must comply with institutional biosafety protocols and relevant regulations.

References

• Falutz J. et al. 'Metabolic Effects of Tesamorelin in HIV-Associated Lipodystrophy.' New England Journal of Medicine, 2010.
• Stanley TL. et al. 'Reduction of Liver Fat with Tesamorelin in HIV Patients.' JAMA, 2014.
• DrugBank: Tesamorelin (DB08869) – Pharmacodynamics and Structure, 2022.
• NDA 22-505 Chemistry Review. U.S. FDA, 2010.
• Cohen RM. et al. 'GH Secretagogues and Pituitary Modulation: Tesamorelin Comparative Studies.' Neuroendocrinology, 2021.